Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 5NIH 5NETWORK 3INDUSTRY 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Dermatologic 5Genitourinary 1

Conditions

Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 13Colorectal Neoplasms 11Rectal Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia 10Head and Neck Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Leukemia, Myeloid, Acute 8Colonic Neoplasms 8Kidney Neoplasms 7Congenital Abnormalities 7Carcinoma, Renal Cell 7Multiple Myeloma 6Lymphoma, Large B-Cell, Diffuse 6Gliosarcoma 6Glioblastoma 6Melanoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Anaplastic 5Esophageal Neoplasms 5Central Nervous System Neoplasms 5Stomach Neoplasms 4Prostatic Neoplasms 4Precancerous Conditions 4Myelodysplastic Syndromes 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Melanoma × Gene Expression Profiling × Clear all
NCT00617799 2023-10-10

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

University of Nebraska

Completed
15 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT04285749 2020-07-27

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Melanoma

NCT00991991 2016-05-17

Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Case Comprehensive Cancer Center

Terminated
5 enrolled
Dermatologic

Melanoma

NCT00565968 2015-03-06

Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

Duke University

Phase 1 Completed
20 enrolled
Dermatologic

Melanoma

NCT00466687 2013-07-22

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡